Orion Oyj (ORNAV.HE)
- Previous Close
33.55 - Open
33.75 - Bid 35.40 x --
- Ask 35.55 x --
- Day's Range
32.95 - 35.65 - 52 Week Range
32.50 - 47.00 - Volume
32,563 - Avg. Volume
6,948 - Market Cap (intraday)
4.93B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
23.02 - EPS (TTM)
1.54 - Earnings Date --
- Forward Dividend & Yield 1.62 (4.83%)
- Ex-Dividend Date Oct 15, 2024
- 1y Target Est
--
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
www.orion.fi3,632
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ORNAV.HE
Performance Overview: ORNAV.HE
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORNAV.HE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORNAV.HE
Valuation Measures
Market Cap
4.67B
Enterprise Value
4.76B
Trailing P/E
21.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.96
Price/Book (mrq)
5.30
Enterprise Value/Revenue
4.00
Enterprise Value/EBITDA
14.48
Financial Highlights
Profitability and Income Statement
Profit Margin
18.22%
Return on Assets (ttm)
10.10%
Return on Equity (ttm)
24.11%
Revenue (ttm)
1.19B
Net Income Avi to Common (ttm)
216.8M
Diluted EPS (ttm)
1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
106.7M
Total Debt/Equity (mrq)
22.47%
Levered Free Cash Flow (ttm)
-103.62M
Company Insights: ORNAV.HE
ORNAV.HE does not have Company Insights